CAMP4 THERAPEUTICS CORP
CAMPNASDAQπ #3342 by market capEarnings Mar 3US Equity
ββ
Quote unavailableTrack CAMP
Get earnings, price moves & breaking news on Telegram
24hβ
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$238M
Small Cap
πRevenue Growth (YoY)
5.6%
Slowing
πGross Margin
35.8%
Healthy
π΅FCF Margin
β
βοΈP/S Ratio
0.0x
Cheap
Otter Score
64
Fair
No chart data available for CAMP.
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $2.90 β $7.75
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 62.8M
- Next Earnings
- 2027-03-03
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $2M
- P/E Ratio
- β
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.20
- Dividend Yield
- β
- Dilution (1yr)
- +166.1%
CAMP4 THERAPEUTICS CORP
CAMPFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3Mβ² +436.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
53.1%βΌ β46.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$52MβΌ β1.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$30MβΌ β35.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
51.9Mβ² +166.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$108Mβ² +$52M YoY
About CAMP4 THERAPEUTICS CORP
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Fair
64/100
Analyst Ratings
βConsensus
Buy
16 analysts
Strong Buy7
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.